Day One Biopharmaceuticals Insider Trading Alert: Preview of Earnings

Day One Biopharmaceuticals is gearing up to release its quarterly earnings data on July 8th, providing investors with a keen insight into the company’s financial health. Analysts are predicting revenue of $36,644,907 and anticipate earnings of -$0.36 per share, setting the stage for an important announcement that could impact the stock’s performance.

For those interested in tracking insider trading and hedge fund activity related to Day One Biopharmaceuticals, Quiver Quantitative’s $DAWN stock page offers a comprehensive overview of the latest developments. Insider trading activity in the past 6 months has seen insiders engage in transactions 7 times, with notable sales reported. Chief Executive Officer Jeremy Bender, General Counsel Adam Dubow, and COO, CFO, and Secretary Charles N II York have all sold shares, indicating a level of activity among company executives.

Hedge fund activity surrounding Day One Biopharmaceuticals has also been noteworthy, with 106 institutional investors adding shares to their portfolio and 65 decreasing their positions in the most recent quarter. Significant moves included Fairmount Funds Management LLC removing a substantial amount of shares from their portfolio, while Polar Capital Holdings PLC made a significant addition to their holdings. These actions by institutional investors provide valuable insights into market sentiment and the perceived value of the company’s stock.

It is essential to stay informed about these developments through resources like Quiver Quantitative’s insider trading dashboard and institutional holdings dashboard to track these activities accurately. While this article serves as an informational piece, it is crucial to note that it does not constitute financial advice. Investors should conduct their research and due diligence before making any investment decisions based on the information provided.

As we await the upcoming earnings release from Day One Biopharmaceuticals, market watchers and investors are anticipating how the financial results will impact the company’s stock performance. Keep a close eye on the latest updates regarding insider trading and hedge fund activity to stay informed about market sentiment surrounding Day One Biopharmaceuticals.